Legal status · Australia
Is DT2216 legal in Australia?
Written by Aaron CuhaReviewed Sep 2026
Direct answer
No. DT2216 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
DT2216 in Australia at a glance
| Classification | Investigational, not registered |
|---|---|
| TGA approval status | Not approved by TGA; investigational |
| Human studies cited | 4 of 6 citations on the profile |
| Reviewed | Sep 2026 |
Classification and note come from the DT2216 profile, checked against Therapeutic Goods Administration (TGA) listings at the reviewed date.
What this means
- 01
DT2216 is being studied in registered clinical trials but has not received TGA marketing approval in Australia.
- 02
Lawful human access is limited to trial participation or a formal early-access scheme where one exists; there is no pharmacy product to prescribe.
- 03
Vials sold online "for research use only" are not trial material, and that label does not make human use lawful.
What DT2216 is
The engineered answer to the navitoclax platelet problem: a degrader that hands BCL-xL to an E3 ligase platelets barely express. In the first human trial, 20 patients with solid tumours, only one dose-limiting toxicity occurred, a grade 4 thrombocytopenia that resolved within 48 hours.
Navitoclax kills senescent cells and platelets through the same target. DT2216 was designed around that.
Mechanism: Established in human cell lines and mice, with the intended platelet sparing now supported by human phase 1 data: DT2216 binds BCL-xL and recruits the VHL E3 ubiquitin ligase, marking BCL-xL for proteasomal degradation. Because VHL is minimally expressed in platelets, the degradation is inefficient there.
Regulatory history: Not approved. Investigational in oncology. First-in-human phase 1 completed with a recommended phase 2 dose of 0.4 mg/kg intravenously twice weekly; no ageing or senescence indication is registered.
How TGA treats this kind of product
Registers or lists therapeutic goods on the ARTG and schedules substances in the Poisons Standard. Many peptides are Schedule 4 (prescription only), so possession without a prescription and personal importation are restricted even when no product is registered.
The classification above is the The Longevity Archive reading of Therapeutic Goods Administration listings for DT2216 at the reviewed date, not a legal opinion. Rules change, and importing, prescribing and possessing a compound can each be treated differently. Check the regulator directly before acting on anything here.
DT2216 in other countries
Frequently asked questions
Is DT2216 legal in Australia?
No. DT2216 is not approved for any medical use in Australia; its classification is "Investigational, not registered". Lawful access is limited to registered clinical trials. "Research use only" labeling on vials sold online does not make human use lawful. On the evidence, 4 human studies are cited on its profile.
Can I buy DT2216 in Australia?
No approved product exists to buy. In Australia DT2216 is classified as "Investigational, not registered", so there is no licensed pharmacy product. Vendors selling it "for research use only" are not selling it for human use, and that label does not change its legal status. This site does not list or recommend vendors.
Is DT2216 TGA approved?
No. In Australia DT2216 is classified as "Investigational, not registered", which is not a TGA marketing approval. For comparison, the US FDA status is: Not approved. Investigational in oncology. First-in-human phase 1 completed with a recommended phase 2 dose of 0.4 mg/kg intravenously twice weekly; no ageing or senescence indication is registered.. On the evidence, 4 human studies are cited on its profile.
Related compounds in Australia
Full research profile
Mechanism, cited studies, FDA status and the full legal summary for DT2216 live on its compound profile.
DT2216 profileThis page is general information about the regulatory status of DT2216 in Australia, current as of Sep 2026. It is not legal advice, and classifications change; check Therapeutic Goods Administration directly or consult a lawyer for a specific situation. Educational use only. This database summarizes published research. It is not medical advice and contains no dosing protocols or recommendations for personal use. The Longevity Archive has no vendor relationships and does not recommend where to buy anything.